Danazol interactions
Medicines
227 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amlodipine Besilate + Atorvastatin | Major | Metabolism | The use of danazol with higher dosages of certain HMG-CoA reductase inhibitors may be associated with an increased risk of myopathy. The proposed mechanism is… | 15 sources — open the full entry |
| Atorvastatin + Ezetimibe | Major | Metabolism | The use of danazol with higher dosages of certain HMG-CoA reductase inhibitors may be associated with an increased risk of myopathy. The proposed mechanism is… | 15 sources — open the full entry |
| Atorvastatin Calcium | Major | Metabolism | The use of danazol with higher dosages of certain HMG-CoA reductase inhibitors may be associated with an increased risk of myopathy. The proposed mechanism is… | 15 sources — open the full entry |
| Carfilzomib | Major | Synergy | Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent… | 3 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Simvastatin | Major | Metabolism | The use of danazol with higher dosages of certain HMG-CoA reductase inhibitors may be associated with an increased risk of myopathy. The proposed mechanism is… | 13 sources — open the full entry |
| Warfarin Sodium | Major | Synergy | Androgens and anabolic steroids may potentiate the hypoprothrombinemic response to oral anticoagulants and increase the risk of bleeding. The onset of… | 58 sources — open the full entry |
| Acalabrutinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Acarbose | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of alfuzosin, which is primarily metabolized by the isoenzyme… | 2 sources — open the full entry |
| Alogliptin Benzoate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these… | 5 sources — open the full entry |
| Axitinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Biphasic Insulin Aspart | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of bosentan, which is metabolized by these isoenzymes… | 1 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme. | 5 sources — open the full entry |
| Bromocriptine Mesylate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of bromocriptine. Orally administered bromocriptine is extensively… | 7 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTablet | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide (Nasal Spray) | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Canagliflozin Hemihydrate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Danazol may increase carbamazepine levels by inhibiting the CYP450 3A4 hepatic metabolism of carbamazepine. Carbamazepine toxicity is possible. | 5 sources — open the full entry |
| Cariprazine | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine… | 5 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is… | 2 sources — open the full entry |
| Cilostazol | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active… | 11 sources — open the full entry |
| Crizotinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of crizotinib, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Metabolism | Danazol may inhibit the CYP450 3A4 hepatic metabolism of cyclosporine. Trough and steady state levels, and the risk of cyclosporine nephrotoxicity may be… | 17 sources — open the full entry |
| Dapagliflozin Propanediol | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Darifenacin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Dasatinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by… | 4 sources — open the full entry |
| Docetaxel Trihydrate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of docetaxel… | 18 sources — open the full entry |
| Drospirenone | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme. | 9 sources — open the full entry |
| Drospirenone + Estetrol | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme. | 9 sources — open the full entry |
| Drospirenone + Estradiol | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme. | 9 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme. | 9 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of drospirenone, which is partially metabolized by the isoenzyme. | 9 sources — open the full entry |
| Dulaglutide | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Dutasteride | Moderate | Metabolism | Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the… | 1 sources — open the full entry |
| Efavirenz | Moderate | Synergy | Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with… | 7 sources — open the full entry |
| Elagolix Sodium | Moderate | Metabolism | Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Empagliflozin | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Empagliflozin + Linagliptin | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms | 95 sources — open the full entry |
| Empagliflozin + Metformin Hydrochloride | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms | 95 sources — open the full entry |
| Enzalutamide | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8… | 1 sources — open the full entry |
| Epirubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes… | 4 sources — open the full entry |
| Ergometrine Maleate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme… | 57 sources — open the full entry |
| Ertugliflozin | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Everolimus | Moderate | Absorption | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration… | 4 sources — open the full entry |
| Fentanyl Citrate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fentanyl, which is primarily metabolized by the isoenzyme. Increased… | 10 sources — open the full entry |
Conditions
Conditions in which Danazol needs care, as documented in this source.
Heart Failure
MajorDanazol is contraindicated in patients with marked impaired cardiac function.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):
Intracranial Hypertension
MajorIntracranial hypertension (pseudotumor cerebri) has occurred in patients receiving danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to cerebral or papilledema and/or intracranial hypertension.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):
Kidney Failure, Chronic
MajorDanazol possess androgenic activity that can result in salt and water retention. Danazol is eliminated by the kidney, and its use is contraindicated in patients with severe renal dysfunction. It should also be administered cautiously in patients adversely affected by volume overload, such as patients suffering from epilepsy, diabetes mellitus, migraine, cardiac or renal dysfunction, polycythemia and hypertension. These patients will require careful observation.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):
Liver Diseases
MajorThe use of danazol is contraindicated in patients with severe hepatic impairment. Danazol is metabolized by the liver to inactive forms. Metabolic and therapeutic activity of danazol may be altered in patients with severe hepatic dysfunction. Elevated serum transaminase levels, peliosis hepatis and benign hepatic adenoma have occurred during chronic administration of danazol. Therapy with danazol should be administered cautiously in patients with or predisposed to hepatic dysfunction.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):
Metrorrhagia
MajorThe use of danazol is contraindicated in patients with undiagnosed, abnormal genital bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present. Alterations of menstruation including irregular cycles, amenorrhea, breakthrough bleeding, and spotting have occurred during danazol therapy.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):
Porphyrias
MajorThe use of danazol is contraindicated in patients with porphyria. Danazol can induce production of delta- aminolevulinic acid (ALA) synthetase activity resulting in porphyrin metabolism.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):
Prostatic Neoplasms
MajorThe use of danazol is contraindicated in patients with androgen- dependent tumors.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):
Thromboembolism
MajorDanazol is contraindicated in patients with thrombosis or thromboembolic disease or a history of such events. Thromboembolism, thrombotic and thrombophlebitic events, including fatal strokes, have occurred during danazol therapy. Hematuria, menstrual spotting and thrombocytopenia have also occurred. Additionally, therapy with danazol should be administered cautiously in patients with or predisposed to bleeding/clotting disorders.
1 source
- "Product Information. Danocrine (danazol)." Sanofi Winthrop Pharmaceuticals (2001):